You have 9 free searches left this month | to do more

empagliflozin

Empagliflozin is a drug used to treat Diabetes Mellitus, Type 2, Healthy, Heart Failure, and other conditions. Empagliflozin is being actively studied in 37 studies and prior, has been studied in 61.

Top SponsorsTop SitesTop Investigators
Boehringer IngelheimCharite - Universitatsmedizin BerlinAnton Borisov
EMSEast Coast Institute for Research, LLCCHEOL WHAN LEE, M.D., Ph.D
Getz PharmaThe University of North Carolina at Chapel HillCaroline M Kistorp
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Completed
  • Type 2 Diabetes Mellitus
  • Seoul, Korea, Republic of
    Clinical Pharmacology, Asan Medical Center
2021-11-08
Nov 8, 2021
S
Not yet recruiting
  • Metabolic-associated Fatty Liver Disease
  • Type 2 Diabetes
  • Empagliflozin
  • +2 more
  • (no location specified)
2021-12-15
Dec 15, 2021
O
Not yet recruiting
  • type1diabetes
  • Empagliflozin
  • Columbus, Ohio
    Ohio State University
2021-06-07
Jun 7, 2021
U
Not yet recruiting
  • Postprandial Hypoglycemia
  • empagliflozin
  • +3 more
  • Basel, Switzerland
    Department of Endocrinology, Diabetes and Metabolism, University
2022-01-19
Jan 19, 2022
B
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +2 more
  • Boston, Massachusetts
    Bringham Women Hospital
2022-04-04
Apr 4, 2022
H
Recruiting
  • Glycogen Storage Disease Type IB
  • Empagliflozin
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
2021-08-08
Aug 8, 2021
M
Not yet recruiting
  • Atrial Fibrillation
  • +3 more
  • Empagliflozin
  • Placebo
  • Acquaviva Delle Fonti, Bari, Italy
    Miulli General Hospital
2021-04-01
Apr 1, 2021
B
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +3 more
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
2022-01-18
Jan 18, 2022
C
Active, not recruiting
  • Type2 Diabetes
  • Cheonju, Chungcheongbuk-do, Korea, Republic of
    Chungbuk National University Hospital
2021-11-02
Nov 2, 2021
U
Completed
  • End Stage Renal Disease
  • Empagliflozin
  • Placebo
  • Pisa, Italy
    Department of Endocrinology and Metabolism, University of Pisa
2021-09-13
Sep 13, 2021
C
Not yet recruiting
  • Glucose 6 Phosphatase Deficiency
  • Empagliflozin
  • Warsaw, Poland
    The Children's Memorial Health Institute
2021-06-18
Jun 18, 2021
N
Recruiting
  • Crohn's Disease
  • +2 more
  • Empagliflozin
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Completed
  • Heart Failure, Diastolic
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Standard care
  • Moscow, Russian Federation
    National Medical Research Center for Cardiology
2022-01-10
Jan 10, 2022
B
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)
  • Aarhus, Denmark
    Department of Clinical Epidemiology - Aarhus Unversiteteshospita
2022-03-07
Mar 7, 2022
G
Active, not recruiting
  • Type II Diabetes Mellitus
  • +2 more
  • Empagliflozin
  • Islamabad, Pakistan
    Umar Diabetes Foundation
2021-12-20
Dec 20, 2021
B
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim International GmbH
2022-04-05
Apr 5, 2022
U
Recruiting
  • Cardiovascular Diseases
  • Left Ventricular Hypertrophy
  • Empagliflozin
  • Placebo
  • Toronto, Ontario, Canada
  • +3 more
2021-06-14
Jun 14, 2021
B
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • empagliflozin
  • +2 more
  • Ridgefield, Connecticut
    Boehringer Ingelheim Pharmaceuticals Inc
2022-03-07
Mar 7, 2022
H
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Placebo
  • Hellerup, Denmark
    Center for Diabetes Research, Gentofte Hospital
2021-06-09
Jun 9, 2021
I
Completed
  • Cardiovascular Diseases
  • Empagliflozin
  • Placebos
  • New York, New York
    Mount Sinai Heart - Icahn School of Medicine at Mount Sinai
2021-03-02
Mar 2, 2021
M
Active, not recruiting
  • NASH
  • +7 more
  • MET409 Active
  • +2 more
  • Fort Myers, Florida
  • +1 more
2021-05-28
May 28, 2021